UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
I-MAB
(Name of Issuer)
Ordinary Shares, par value $0.0001**
American Depositary Shares
(Title of Class of Securities)
44975P103**
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
¨ Rule 13d-1(c)
x Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the ADSs of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADSs represents 23 Ordinary Shares.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 2 of 17 Pages |
| 1 |
NAMES OF REPORTING PERSONS
IBC Investment Seven Limited
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Hong Kong
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
3,931,802
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
3,931,802
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,931,802
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ | ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.4%1
| ||
| 12 |
TYPE OF REPORTING PERSON
CO | ||
1 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 3 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
CBC SPVII LIMITED
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Hong Kong
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
5,574,560
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
5,574,560
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,574,560
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.4%2
| ||
| 12 |
TYPE OF REPORTING PERSON
CO | ||
2 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 4 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
CBC Investment I-Mab Limited
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
12,229,916
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
12,229,916
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
12,229,916
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.4%3
| ||
| 12 |
TYPE OF REPORTING PERSON
CO | ||
3 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 5 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
C-Bridge II Investment Ten Limited
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
2,369,546
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
2,369,546
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,369,546
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
1.4%4
| ||
| 12 |
TYPE OF REPORTING PERSON
CO | ||
4 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 6 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
Everest Medicines Limited
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
6,078,571
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
6,078,571
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,078,571
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.7%5
| ||
| 12 |
TYPE OF REPORTING PERSON
CO
| ||
5 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 7 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
C-Bridge II Investment Thirteen Limited
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
859,181
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
859,181
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
859,1816
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.5%7
| ||
| 12 |
TYPE OF REPORTING PERSON
CO
| ||
6 Represented by 373,557 American depositary shares of the Issuer
7 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 8 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
C-Bridge Healthcare Fund II, L.P.
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
15,458,643
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
15,458,643
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,458,6438
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%9
| ||
| 12 |
TYPE OF REPORTING PERSON
PN
| ||
8 Including 859,181 ordinary shares represented by 373,557 American depositary shares of the Issuer
9 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 9 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
C-Bridge Healthcare Fund GP II, L.P.
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
15,458,643
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
15,458,643
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,458,64310
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.3%11
| ||
| 12 |
TYPE OF REPORTING PERSON
PN
| ||
10 Including 859,181 ordinary shares represented by 373,557 American depositary shares of the Issuer
11 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
|
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 10 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
C-Bridge Capital GP, Ltd.
| ||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý | ||
| 3 |
SEC USE ONLY
| ||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
| ||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 |
SOLE VOTING POWER
0
| |
| 6 |
SHARED VOTING POWER
24,965,005
| ||
| 7 |
SOLE DISPOSITIVE POWER
0
| ||
| 8 |
SHARED DISPOSITIVE POWER
24,965,005
| ||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
24,965,00512
| ||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
| ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
15.1%13
| ||
| 12 |
TYPE OF REPORTING PERSON
CO
| ||
12 Including 859,181 ordinary shares represented by 373,557 American depositary shares of the Issuer
13 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 11 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
I-Bridge Healthcare Fund, L.P.
|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý |
| 3 | SEC USE ONLY
|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 | SOLE VOTING POWER
0
|
| 6 | SHARED VOTING POWER
9,506,362
| |
| 7 | SOLE DISPOSITIVE POWER
0
| |
| 8 | SHARED DISPOSITIVE POWER
9,506,362
|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,506,362
|
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.7%14
|
| 12 | TYPE OF REPORTING PERSON
PN
|
14 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 12 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
I-Bridge Healthcare GP, L.P.
|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý |
| 3 | SEC USE ONLY
|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 | SOLE VOTING POWER
0
|
| 6 | SHARED VOTING POWER
9,506,362
| |
| 7 | SOLE DISPOSITIVE POWER
0
| |
| 8 | SHARED DISPOSITIVE POWER
9,506,362
|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,506,362
|
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.7% 15
|
| 12 | TYPE OF REPORTING PERSON
PN
|
15 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 13 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
I-Bridge Capital GP, Ltd.
|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý |
| 3 | SEC USE ONLY
|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 | SOLE VOTING POWER
0
|
| 6 | SHARED VOTING POWER
9,506,362
| |
| 7 | SOLE DISPOSITIVE POWER
0
| |
| 8 | SHARED DISPOSITIVE POWER
9,506,362
|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,506,362
|
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.7%16
|
| 12 | TYPE OF REPORTING PERSON
CO
|
16 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 14 of 17 Pages |
1 |
NAMES OF REPORTING PERSONS
Wei Fu
|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý |
| 3 | SEC USE ONLY
|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Singapore
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5 | SOLE VOTING POWER
0
|
| 6 | SHARED VOTING POWER
31,043,576
| |
| 7 | SOLE DISPOSITIVE POWER
0
| |
| 8 | SHARED DISPOSITIVE POWER
31,043,576
|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
31,043,57617
|
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
18.8%18
|
| 12 | TYPE OF REPORTING PERSON
IN
|
17 Including 859,181 ordinary shares represented by 373,557 American depositary shares of the Issuer
18 Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 15 of 17 Pages |
| Item 1(a) | Name of Issuer: |
I-MAB (the “Issuer”)
| Item 1(b) | Address of Issuer’s Principal Executive Offices: |
Suite 802, West Tower, OmniVision
88 Shangke Road, Pudong District
Shanghai, 201210
People’s Republic of China
| Item 2(a) | Name of Persons Filing: |
This Schedule 13G is filed by and on behalf of:
| 1. | IBC Investment Seven Limited |
| 2. | CBC SPVII LIMITED |
| 3. | CBC Investment I-Mab Limited |
| 4. | C-Bridge II Investment Ten Limited |
| 5. | Everest Medicines Limited |
| 6. | C-Bridge II Investment Thirteen Limited |
| 7. | C-Bridge Healthcare Fund II, L.P. |
| 8. | C-Bridge Healthcare Fund GP II, L.P. |
| 9. | C-Bridge Capital GP, Ltd. |
| 10. | I-Bridge Healthcare Fund, L.P. |
| 11. | I-Bridge Healthcare GP, L.P. |
| 12. | I-Bridge Capital GP, Ltd. |
| 13. | Wei Fu |
This statement on Schedule 13G relates to securities directly held by IBC Investment Seven Limited, CBC SPVII LIMITED, CBC Investment I-Mab Limited, C-Bridge II Investment Ten Limited, Everest Medicines Limited, and C-Bridge II Investment Thirteen Limited.
CBC Investment I-Mab Limited, C-Bridge II Investment Ten Limited and C-Bridge II Investment Thirteen Limited are controlled by C-Bridge Healthcare Fund II, L.P., whose general partner is C-Bridge Healthcare Fund GP II, L.P., and its general partner is C-Bridge Capital GP, Ltd.
CBC SPVII Limited and IBC Investment Seven Limited are controlled by I-Bridge Healthcare Fund, L.P., whose general partner is I-Bridge Healthcare GP, L.P., and its general partner is I-Bridge Capital GP, Ltd., which is indirectly controlled by C-Bridge Capital GP, Ltd.
Mr. Wei Fu is the sole director of C-Bridge Capital GP, Ltd.
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 16 of 17 Pages |
Everest Medicines Limited is a public company listed on the Hong Kong Stock Exchange and controlled by funds which are under common control of the C-Bridge group, which, in turn, is controlled by Mr. Wei Fu.
C-Bridge Healthcare Fund II, L.P., C-Bridge Healthcare Fund GP II, L.P., C-Bridge Capital GP, Ltd., I-Bridge Healthcare Fund, L.P., I-Bridge Healthcare GP, L.P., I-Bridge Capital GP, Ltd., and Mr. Wei Fu may be deemed to beneficially own the securities of the Issuer owned by the entities which they control.
| Item 2(b) | Address of Principal Business Office or, If None, Residence |
The business address of each reporting person is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong.
| Item 2(c) | Citizenship |
| 1. | IBC Investment Seven Limited: Hong Kong |
| 2. | CBC SPVII LIMITED: Hong Kong |
| 3. | CBC Investment I-Mab Limited: British Virgin Islands |
| 4. | C-Bridge II Investment Ten Limited: British Virgin Islands |
| 5. | Everest Medicines Limited: Cayman Islands |
| 6. | C-Bridge II Investment Thirteen Limited: British Virgin Islands |
| 7. | C-Bridge Healthcare Fund II, L.P.: Cayman Islands |
| 8. | C-Bridge Healthcare Fund GP II, L.P.: Cayman Islands |
| 9. | C-Bridge Capital GP, Ltd.: Cayman Islands |
| 10. | I-Bridge Healthcare Fund, L.P.: Cayman Islands |
| 11. | I-Bridge Healthcare GP, L.P.: Cayman Islands |
| 12. | I-Bridge Capital GP, Ltd.: Cayman Islands |
| 13. | Wei Fu: Singapore |
| Item 2(d) | Title of Class of Securities: |
Ordinary Shares, par value $0.0001
| Item 2(e) | CUSIP Number: |
44975P103
| Item 3. | Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c): |
Not applicable.
| Item 4. | Ownership |
The information for each reporting person contained in rows 5-11 of the cover pages and Item 2(a) is incorporated herein by reference.
CUSIP No. 44975P103
|
SCHEDULE 13G | Page 17 of 17 Pages |
| Item 5. | Ownership of Five Percent or Less of a Class |
Not applicable.
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person |
Not applicable.
| Item 7. | Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group |
Not applicable.
| Item 9. | Notice of Dissolution of Group |
Not applicable.
| Item 10. | Certifications |
Not applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 12, 2021
| IBC Investment Seven Limited | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| CBC SPVII LIMITED | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| CBC Investment I-Mab Limited | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| C-Bridge II Investment Ten Limited | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| Everest Medicines Limited | ||
| By: | /s/ Xiaofan ZHANG | |
| Name: | Xiaofan ZHANG | |
| Title: | Director | |
| C-Bridge II Investment Thirteen Limited | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| C-Bridge Healthcare Fund II, L.P. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Authorized Representative | |
| C-Bridge Healthcare Fund GP II, L.P. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Authorized Representative | |
| C-Bridge Capital GP, Ltd. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| I-Bridge Healthcare Fund, L.P. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Authorized Representative | |
| I-Bridge Healthcare GP, L.P. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Authorized Representative | |
| I-Bridge Capital GP, Ltd. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| Wei Fu | ||
| By: | /s/ Wei FU | |
LIST OF EXHIBITS
Exhibit No. Description
| 1 | Joint Filing Agreement dated as of February 12, 2021 by and among the reporting persons |
Exhibit 1
Joint Filing Agreement
In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Ordinary Shares, par value $0.0001, of I-MAB and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filing. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of February 12, 2021. This Agreement may be executed in any number of counterparts, all of which, taken together, shall constitute one and the same instrument.
| IBC Investment Seven Limited | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| CBC SPVII LIMITED | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| CBC Investment I-Mab Limited | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| C-Bridge II Investment Ten Limited | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| Everest Medicines Limited | ||
| By: | /s/ Xiaofan ZHANG | |
| Name: | Xiaofan ZHANG | |
| Title: | Director | |
| C-Bridge II Investment Thirteen Limited | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| C-Bridge Healthcare Fund II, L.P. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Authorized Representative | |
| C-Bridge Healthcare Fund GP II, L.P. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Authorized Representative | |
| C-Bridge Capital GP, Ltd. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| I-Bridge Healthcare Fund, L.P. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Authorized Representative | |
| I-Bridge Healthcare GP, L.P. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Authorized Representative | |
| I-Bridge Capital GP, Ltd. | ||
| By: | /s/ Wei FU | |
| Name: | Wei FU | |
| Title: | Director | |
| Wei Fu | ||
| By: | /s/ Wei FU | |